• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.评估临床环境中氯胺酮和艾司氯胺酮治疗对抑郁严重程度的影响。
JAMA Psychiatry. 2022 Jul 1;79(7):736-738. doi: 10.1001/jamapsychiatry.2022.1074.
2
Esketamine for treatment resistant depression: a trick of smoke and mirrors?用于治疗抵抗性抑郁症的 Esketamine：烟雾与镜子的把戏？
Epidemiol Psychiatr Sci. 2019 Dec 16;29:e79. doi: 10.1017/S2045796019000751.
3
Intranasal esketamine for depression: Not so special K.鼻腔内给予氯胺酮治疗抑郁症：并非如此特别。
Australas Psychiatry. 2022 Aug;30(4):533-534. doi: 10.1177/10398562221093870. Epub 2022 May 1.
4
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.总结氯胺酮和艾司氯胺酮治疗难治性抑郁症的证据：现有证据和实施情况的国际专家意见。
Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17.
5
Esketamine for treatment resistant depression.艾氯胺酮用于治疗难治性抑郁症。
Expert Rev Neurother. 2019 Oct;19(10):899-911. doi: 10.1080/14737175.2019.1640604. Epub 2019 Jul 16.
6
Esketamine (Spravato) for Treatment-Resistant Depression.艾氯胺酮（斯普拉维托）用于治疗抵抗性抑郁症。
Am Fam Physician. 2020 Mar 15;101(6):339-340.
7
Esketamine as a treatment for paediatric depression: questions of safety and efficacy.艾氯胺酮作为儿童抑郁症的治疗方法：安全性和有效性问题。
Lancet Psychiatry. 2020 Oct;7(10):827-829. doi: 10.1016/S2215-0366(19)30521-8. Epub 2020 Jan 14.
8
Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression.艾氯胺酮治疗难治性抑郁症比喹硫平更有效。
JAMA. 2023 Nov 7;330(17):1611. doi: 10.1001/jama.2023.19797.
9
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.氯胺酮和艾司氯胺酮治疗难治性抑郁症：对雷乌斯、马茨和沙茨伯格的回应。
Am J Psychiatry. 2021 Dec;178(12):1130-1132. doi: 10.1176/appi.ajp.2021.21060653r.
10
Esketamine for resistant depression in older people with cognitive impairment: A case report.艾氯胺酮用于治疗有认知障碍的老年人难治性抑郁症：一例报告。
Encephale. 2023 Dec;49(6):651-653. doi: 10.1016/j.encep.2023.06.010. Epub 2023 Aug 19.

引用本文的文献

1
Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study.接受静脉注射氯胺酮和鼻内艾司氯胺酮治疗的难治性抑郁症患者的长期结局：一项观察性研究。
J Clin Psychiatry. 2025 Jul 30;86(3):25m15831. doi: 10.4088/JCP.25m15831.
2
Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee.在一组接受急性治疗疗程以管理难治性抑郁症的患者中艾氯胺酮的滥用可能性：一项真实世界临床实践中观察性研究的二次分析
Ther Adv Drug Saf. 2025 Jun 19;16:20420986251347360. doi: 10.1177/20420986251347360. eCollection 2025.
3
Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression.基线感知压力作为难治性抑郁症中氯胺酮/艾氯胺酮治疗反应的预测指标。
J Affect Disord. 2025 Aug 15;383:283-289. doi: 10.1016/j.jad.2025.04.117. Epub 2025 Apr 25.
4
Personalized use of ketamine and esketamine for treatment-resistant depression.个体化使用氯胺酮和艾司氯胺酮治疗难治性抑郁症。
Transl Psychiatry. 2024 Nov 29;14(1):481. doi: 10.1038/s41398-024-03180-8.
5
Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis.消旋氯胺酮或艾司氯胺酮单药治疗对减轻单相或双相抑郁症患者自杀观念的疗效：一项系统评价和荟萃分析。
Eur Arch Psychiatry Clin Neurosci. 2024 Oct 9. doi: 10.1007/s00406-024-01920-x.
6
Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study.在复发性重度抑郁症患者中开具氯胺酮处方后出现自杀意念：一项全国性队列研究。
Transl Psychiatry. 2024 Aug 9;14(1):327. doi: 10.1038/s41398-024-03033-4.
7
Esketamine in depression: putative biomarkers from clinical research.艾氯胺酮治疗抑郁症：临床研究中的潜在生物标志物
Eur Arch Psychiatry Clin Neurosci. 2024 Jul 13. doi: 10.1007/s00406-024-01865-1.
8
Widespread reductions in cortical thickness following ketamine abuse.广泛的皮质厚度减少后，滥用氯胺酮。
J Psychiatry Neurosci. 2024 May 30;49(3):E182-E191. doi: 10.1503/jpn.230111. Print 2024 May-Jun.
9
Ketamine in Substance Use Disorder Treatment: A Narrative Review.氯胺酮在物质使用障碍治疗中的应用：一项叙述性综述。
Alpha Psychiatry. 2024 Mar 1;25(2):206-211. doi: 10.5152/alphapsychiatry.2024.241522. eCollection 2024 Mar.
10
Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023.近年来治疗抵抗性抑郁症的治疗进展：2018 年至 2023 年文献综述。
Curr Psychiatry Rep. 2024 Apr;26(4):176-213. doi: 10.1007/s11920-024-01494-4. Epub 2024 Feb 22.

本文引用的文献

1
A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.真实医疗环境下氯胺酮静脉治疗抑郁症的回顾性分析。
J Affect Disord. 2022 Mar 15;301:486-495. doi: 10.1016/j.jad.2021.12.097. Epub 2022 Jan 11.
2
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.消旋卡前列素与依他佐辛治疗抑郁症的疗效比较：系统评价和荟萃分析。
J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23.
3
Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review.门诊抑郁症患者采用急性和维持性静脉注射氯胺酮治疗的长期结局：回顾性图表分析。
J Affect Disord. 2020 Nov 1;276:660-666. doi: 10.1016/j.jad.2020.07.089. Epub 2020 Jul 20.
4
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.使用 Esketamine 或消旋 Ketamine 辅助治疗成人治疗抵抗性抑郁症的疗效和安全性：一项随机、双盲、非劣效性研究。
J Affect Disord. 2020 Mar 1;264:527-534. doi: 10.1016/j.jad.2019.11.086. Epub 2019 Nov 14.
5
The cost of dichotomising continuous variables.将连续变量二分的代价。
BMJ. 2006 May 6;332(7549):1080. doi: 10.1136/bmj.332.7549.1080.
6
Antidepressant effects of ketamine in depressed patients.氯胺酮对抑郁症患者的抗抑郁作用。
Biol Psychiatry. 2000 Feb 15;47(4):351-4. doi: 10.1016/s0006-3223(99)00230-9.

评估临床环境中氯胺酮和艾司氯胺酮治疗对抑郁严重程度的影响。

Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.

机构信息

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.

Yale University, New Haven, Connecticut.

出版信息

JAMA Psychiatry. 2022 Jul 1;79(7):736-738. doi: 10.1001/jamapsychiatry.2022.1074.

DOI:10.1001/jamapsychiatry.2022.1074
PMID:35544190
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9096687/
Abstract

This comparative analysis examines the trajectory of depression severity among patients treated with intravenous ketamine or intranasal esketamine in a clinical setting.

摘要

本对比分析研究了在临床环境中接受静脉注射氯胺酮或鼻内依他佐辛治疗的患者的抑郁严重程度的变化轨迹。